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I N T R O D U C T I O N
Hypertension and chronic kidney disease (CKD) represent a global public health burden due to their worldwide epidemic prevalence and their close association [1] [2] [3] . Hypertension is a leading cause of CKD and a decrease in glomerular filtration rate (GFR) is associated with a higher prevalence of hypertension and an increased proportion of suboptimal blood pressure (BP) control [4, 5] . In addition, based on evidence from endstage renal disease (ESRD) registries [2] , the link between hypertension and CKD has been evaluated in large unselected population studies, with conflicting results about the role of hypertension on GFR decline [6] [7] [8] . Overall, there is little information on the development and/or progression of CKD over time during the natural history of treated arterial hypertension. Analysis of CKD progression can allows us to determine factors facilitating the worsening of arterial hypertension and to identify phenotypes at risk. Accordingly, we analysed factors associated with GFR decline in a large registry of treated hypertensive outpatients from southern Italy. 
T E R I A L S A N D M E T H O D S

Participants
The Campania Salute Network (CSN) is an open registry collecting information from general practitioners and community hospitals in the five districts of the Campania Region in southern Italy. General practitioners and physicians in community hospitals are networked with the Hypertension Center of the Federico II University Hospital in Naples. The database generation from the CSN was approved by our institutional ethics committee and all participants provided signed informed consent. All hypertensive patients from the network were referred to our Hypertension Center for baseline echocardiograms. Detailed characteristics of the CSN population have been previously reported [9] . Incident atrial fibrillation (AF) and cardiovascular (CV) or cerebrovascular events were adjudicated by the Committee for Event Adjudication in the Hypertension Center. Adjudication was based on the patient's history, contact with the reference general practitioner and clinical records [10] . For the present analysis, the 2016 release of the CSN database was used, which excluded the majority of hypertensive patients with concomitant coronary artery disease, valve disease and low ejection fraction. Hypertensive subjects with a history of AF and prevalent CV disease (myocardial infarction, coronary revascularization, carotid stenting and heart failure), valve heart disease, hyperthyroidism, low left ventricular (LV) ejection fraction (EF) (<50%), Stage IV or V CKD and <3 years of follow-up (FU) ( Figure 1 ) were also excluded. Thus, the study population comprised 4539 hypertensive patients.
Outcome
GFR decline was the endpoint of the present analysis. GFR was measured by the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation [11] . GFR was measured both at baseline and at the time of the last available visit. GFR decline was defined, as recently suggested [8] , by a !30% decrease in GFR from the initial value for patients in Stage III CKD at baseline or by a composite achieved decrease !30% from baseline and a final value of <60 in patients with baseline GFR !60 mL/min/1.73 m 2 .
Measurements and definitions
Diabetes was defined according to 2007 American Diabetes Association criteria (fasting plasma glucose >125 mg/dL or antidiabetic treatment) [12] . Obesity was defined as a BMI !30 kg/m 2 . Systolic and diastolic BPs were measured by standard aneroid sphygmomanometer after 5 min resting in a sitting position, according to current guidelines. Isolated systolic hypertension (ISH) was defined as a baseline systolic BP !140 mmHg and a baseline diastolic BP <90 mmHg [13] .
BP was evaluated at each visit so that the mean systolic and diastolic BP during FU was obtained for each patient. Optimally controlled BP was defined as a combination of the average systolic BP <140 mmHg and the average diastolic BP <90 mmHg during FU [13] .
Echocardiography
All echocardiograms were recorded on videotape in our Hypertension Center by commercial machines and a standardized protocol. They were digitally remastered and read offline by one expert reader under the supervision of a senior faculty member, on dedicated workstations (MediMatic, Genova, Italy).
Measurements were made according to the American Society of Echocardiography/European Association of Echocardiography recommendations [14] . LV mass was estimated by a necropsyvalidated formula [14] and normalized for height in metres to the power of 2.7 (LVMi) [15] . LV hypertrophy (LVH) was defined as LVMi !50 g/m 2.7 in men and !47 g/m 2.7 in women [15] . Relative wall thickness (RWT), as 2 times posterior wall thickness divided by LV internal radius, was used as a measure of LV concentricity. LV concentric geometry was defined as an RWT !0.43 for both genders. LV volumes were calculated by the zderived method, which has been shown to be the most accurate estimation of LV volume measured by 2D-guided M-mode echocardiography [16] , and used to assess ejection fraction.
Carotid ultrasound
Carotid ultrasound was performed on patients in the supine position, the neck extended in mild rotation. Examinations were recorded on S-VHS videotapes and analysed as previously described [17, 18] . The maximal arterial intima-media thickness (IMT) was estimated offline in up to 12 arterial walls, including the right and the left, near and far distal common carotid (1 cm), bifurcation, and proximal internal carotid artery, using an imageprocessing dedicated workstation (MediMatic, Genova, Italy). Evidence of IMT >1.5 mm was considered as 'plaque' [19] .
Statistical analysis
Data were analysed by SPSS (version 21.0; SPSS, Chicago, IL, USA) and expressed as mean 6 1 SD. Analysis of variance was used to compare patients with or without GFR decline. The v
þþ channel blockers, b-blockers, and thiazide diuretics, were considered as covariates in the multivariate analysis if used in >50% of control visits. Binary logistic regression was applied to isolate independent predictors of incident GFR decline using backward stepwise selection of main potential confounders including age, gender, diabetes, ISH, systolic BP at baseline and during FU and duration of FU. In a second model, markers of preclinical CV disease (LVMi, RWT, ejection fraction, IMT), target organ damage (TOD) (defined as the presence of definite LVH or carotid plaque), incident AF and major CV events were added to the first model. Finally, classes of antihypertensive and antiplatelet medications were forced into the previous model as a third step in the hierarchical procedure. The null hypothesis was rejected at a two-tailed P 0.05.
R E S U L T S
The mean 6 SD age of the study population was 53 6 11 years. The proportion of women was 43%. Obesity was present in 25% and diabetes in 8% of the patients. In the whole study population, 2604 (57%) patients had TOD: LVH was present in 1467 (32%) and carotid plaque in 1893 (42%). After a mean FU of 7.5 years (interquartile range 4-10 years), GFR declined in 432 (10%) patients at a rate of 13 patients/1000/years. FU was significantly longer in patients with declining GFR (P < 0.0001). Table 1 shows that patients with GFR decline were older, more likely to be women and diabetics, with a greater prevalence of ISH; they exhibited lower GFR at baseline, lower LV ejection fraction and higher LV mass (LVM), RWT and IMT (all P < 0.01). As a consequence, TOD was more prevalent in patients with GFR decline than in those with preserved renal function (overall P < 0.0001). Patients with GFR decline also exhibited higher systolic BP and pulse pressure (PP), both at baseline and during FU, and less frequently had well-controlled BP (all P < 0.05). In the subgroup of patients with optimally controlled BP (n ¼ 2818), GFR decline occurred in 228 patients (8.1%), compared with 204 patients (11.9%) with suboptimal BP control (n ¼ 1721; P < 0.0001). The risk of AF was >3-fold higher in patients with GFR decline {odds ratio [OR] 3.29 [95% confidence interval (CI) 2.15-5.04]; P < 0.0001} during FU. Similarly, the rate of major CV events was >2-fold higher in patients with GFR decline [OR 2.31 (95% CI 1.30-4.09); P < 0.01].
Patients experiencing GFR decline took more medications during FU due to more frequent prescriptions of Ca þþ channel blockers, statins, diuretic and anti-RAS (overall P < 0.005; Table 2 ).
In a multivariable logistic regression analysis, the probability of GFR decline during FU was independently associated with older age, diabetes, lower initial GFR, higher systolic BP during FU and FU duration (all P < 0.01; Table 3 , Model 1). LV mass and incident AF were also significant cofactors of GFR decline, independent of the effect of variables in Model 1 (Table 3 , Model 2). Forcing antihypertensive and antiplatelet medications did not change this model.
In the subgroup of 2818 patients with optimally controlled BP, cofactors of GFR decline were older age, lower baseline GFR (Table 4 ; all P < 0.0001), whereas no effect was found for TOD and AF.
D I S C U S S I O N
To our knowledge, this is the first study evaluating the decline of GFR over time as a continuous variable using the CKD-EPI approach in a registry of treated, unselected hypertensive patients [21] . Our study demonstrates that in a hypertension clinic, renal function deteriorates in a substantial proportion of treated hypertensive patients over the FU time. Risk factors for GFR decline were older age, lower GFR and higher LV mass at baseline, higher systolic BP during FU and the occurrence of AF, although patients who developed GFR were prescribed more antihypertensive medications than those preserving renal function. Thus, BP control is confirmed to be an important condition associated with the preservation of kidney function.
Assessment of GFR decline
GFR decline has been considered as an endpoint in a number of clinical and epidemiologic studies [22, 23] . However, in those studies, the definition of GFR decline varies widely, resulting in a difficult interpretation of existing data. In our study, the definition adopted was the one proposed in a scientific workshop endorsed by the National Kidney Foundation and the US Food and Drug Administration: a GFR reduction of !30% in a time span of !3 years [21] . Together with this accepted criterion, we also categorized those patients with an initial GFR !60 mL/ min/1.73 m 2 , whose GFR declined 30% with a final value <60 [21] as showing GFR decline, as there is evidence that Stage III CKD is associated with an adverse CV phenotype [24, 25] .
By these criteria, in our population of treated hypertensive patients, kidney function declined with a rate in line with the incidence rate reported by Wecker et al. [26] in a large population study. However, in that analysis GFR decline was evaluated excluding subjects with Stage III CKD and using the Modification of Diet in Renal Disease equation, while no information on BP measurements during FU was given. The exclusion of patients with Stage III CKD does not represent the real clinical scenario among hypertensive patients, even in the context of the selection we adopted, as Stage III CKD is frequent in the real world of arterial hypertension outpatient clinics. Stage III CKD was, in fact, present at baseline in nearly 8% of patients, a prevalence greater than the one reported in the SPRINT trial (2.2%) [27] , where patients with comorbidities were excluded.
Correlates of GFR decline
Older age and lower values of initial GFR are the main predictors of GFR decline. Even in case of optimally controlled BP, deterioration of kidney function is almost inevitable and the type of antihypertensive therapy has no effect on the progression of CKD.
Kidneys are affected by the ageing process, which results in inexorable GFR decline, as it is accepted worldwide [28] [29] [30] . In our registry, the prevalence of Stage III CKD in patients >70 years of age at baseline was similar to what is reported in the general population (40%) [1] , but it rose to 55% at the end of FU, confirming that hypertension participates in renal function decline over time [2] .
A lower GFR at baseline as a correlate of GFR decline was an expected result [22] . In our population, the risk for GFR decline increased by 11% for each 5 ml of lower initial GFR. All these findings suggest that because of the sensitivity of GFR decline to BP control, and especially in the presence of reduced initial GFR, antihypertensive treatment should be aggressive in order to obtain optimal BP control to counterbalance the risk of GFR decline associated with initially low GFR [31, 32] .
As previously stated, observations on the relation between BP and GFR decline were derived mostly from clinical and epidemiological studies where BP was assessed only at baseline [23, 33] . Rosansky et al. [34] assessed BP during FU in 56 male Table 3 . Multivariate logistic regression analysis displaying the probability of GFR decline in relation to baseline correlates and FU BP Diabetes, markers of preclinical CV disease (RWT, EF, IMT), TOD and incident major CV events did not enter into the model (P > 0.05). Table 4 . Multivariate logistic regression analysis displaying the probability of GFR decline in relation to baseline correlates and FU blood pressure in patients with controlled BP during FU adults and found that the increase in serum creatinine was greater in hypertensives than in normotensives, substantially due to higher mean systolic BP throughout FU. Our results expand this observation on an epidemiological scale and in the specific setting of treated arterial hypertension, demonstrating that the decline of kidney function might be very sensitive to BP control, though the indication of a clear-cut threshold was outside the purpose of the present observational study. It should be noted that the significant association of initial systolic BP and PP with GFR decline, identified in exploratory statistics, disappeared in the multivariable analysis once other cofactors were considered, including the most important, the average value of BP during FU. This finding suggests that BP monitoring is of critical importance to reduce incident GFR decline in hypertensive patients, especially in those who already present with reduced kidney function. This indication is further supported by the evidence that in patients with optimally controlled BP, even the average FU systolic BP was not statistically associated with GFR decline. Of course, we cannot rule out the possibility that GFR decline per se is the cause of difficult BP control during FU due to several mechanisms, including activation of the RAS and increased sympathetic nervous system activities [35, 36] . Also interesting is the observation that both therapy and type of medication did not influence the decline of kidney function. Our analysis, together with previous findings [37, 38] , indicates that greater attention should be paid to calibrating antihypertensive treatment based on the presence of TOD and specifically on evidence of decline of GFR. This finding parallels the emerging evidence that once organ damage is consolidated, return to normality is very difficult, despite aggressive therapy. This has been demonstrated also for LVH and carotid IMT [19, 39] .
High LV mass index was another independent covariate of GFR decline, confirming previous findings [40] . Whether LVH should be considered a marker of progression of renal disease or a factor involved in GFR decline needs to be clarified [41] [42] [43] .
The critical importance of BP control in the preservation of renal function has been recently demonstrated in a large cohort of hypertensive diabetic subjects during an observational 4-year FU study [44] . In our study, we extended this finding to an unselected population in which diabetes was one of the covariates of GFR decline in our first logistic model but was not significantly associated in the final model when the most potent marker of TOD (LV mass) was entered.
Recently CKD was associated with an increased risk of heart failure, coronary artery disease and stroke [45] . In our registry of hypertensive patients, GFR decline has been associated with an increased risk of incident AF, raising interesting questions on the prognostic impact of reduced renal function that need to be further elucidated by future analysis.
Limitations
We based our diagnosis of GFR decline on a single estimate of GFR. Estimated GFR measurements exhibit a high degree of intra-individual variability and ideally require second measurements to accurately represent kidney function [21] . Theoretically, the use of sequential GFR measurements could change the prevalence of CKD and the incidence of GFR decline. However, in addition to the biological plausibility of our findings, even assuming a classification error, our sample size is sufficient to warrant the stability of our results.
Unfortunately, we have no data on proteinuria on an epidemiological scale: some authors have observed that in populationbased cohorts, the rate of decline in kidney function within a given level of GFR varied substantially according to the presence and severity of proteinuria [46] . However, proteinuria is substantially associated with different TODs [47, 48] , and we used two other relevant TODs, including LVH, which is also the most potent predictor of CV complications in arterial hypertension [49, 50] .
We need to underline that the definition of optimally controlled BP adopted in our study has some limitations, since we could not identify patients with albuminuria/proteinuria whose optimal BP control is lower than our generic cut-off of 140/ 90 mmHg [13] .
Another limitation of our study needs to be highlighted: due to the impossibility of a time-dependent analysis on GFR decline, we could not demonstrate a clear cause-effect relationship between our variables and GFR decline. This is particularly important for BP control, as the relationship between BP control and reduced GFR is bidirectional. This bidirectional relationship makes reverse causation possible, i.e. the lack of BP control at the time of our censoring could be due to the decline of GFR. Future longitudinal analyses should be designed specifically to assess a cause-effect relationship.
We conclude that under antihypertensive therapy, kidney function declines in patients with initially low GFR, increased LV mass and suboptimal BP control during FU, despite more aggressive medical therapy.
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